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THE NATURAL HISTORY OF CHRONIC HEPATITIS C IN HAEMOPHILIACS
Makris et al (1996) report thal within 22 years of infection
with hepatitis C virus (HCV). 19% of patients have cirrhpsis
and 9% have developed liver failure. The analysis. which
shows a non-significant increased risk of progression in
those co-infected with HIV, is based on the development of
cirrhosis in 19 individuals out of 138 studied, including
eight with hepatic failure, of whom four were co-infected
with HIV. A number of issues require further comment.
Firstly. the date of the patient's first exposure to clotting
factor concentrate was assumed to be the date of HCV
infection. However, for 25% of the cohort ( 35 patients). this
date was unknown and has been estimated to be l January
1972. or the date of the first birthday in Ihe case of patients
born after this date. A number of problems may arise when
making this assumption. As seroconversion to HCV from
blood product Iherapy occurred in the U.K. äs early äs 1965
and äs late äs 1985, dates of seroconversion to HCV may be
inaccurately estimated in some patients. Further, allhough it
is reasonable to assume thal patients with severe haemo-
philia would have received concentrale by the time of their
iirst birthday, it may be unreasonable to make this
assumption in those with mild or moderate forms of the
condition for whom the date of first infusion could have
occurred at any date. Thus, it would be of inlerest to see the
Kaplan-Meier progression rates calculated only in those 103
patients with documented dates of first exposure to clotting
factor concentrate.
Secondly, although the results from this study are
consistent with those previously reported (Eyster et al
1993; Telfer et al. 1994) in confirming an increased risk of
progression in co-infected individuals, the hazard ratio
associated with co-infeclion is smaller than theit reported
in these previous studies. Makris et al (1996) categorize
patients äs either being infected or uninfected with HIV.
On average, patients in their cohort became infected
with HIV in 1983, some 11 years later than infection with
HCV. If there is any risk of HCV progression associated
with co-infeclion. then it is unlikely to act during these
first 11 years when patients are only infected with HCV.
Further, Ihe individuals who become infecled with HIV must
have survived al leasl 11 years without developing liver
failure. Thus an analysis of Ihis lype is biased towards
showing a betler prognosis in co-infected individuals. A more
appropriate analysis which provides an unbiased estimale
of Ihe hazard ralio associated with HIV infection would
incorporate HIV infection into a Cox proportional hazards
model äs a time-updated covariale. lakmg Ihe value of 0
Table I
ALT level Non-biopsied Biopsied
Persistent h' abnormal
Intermittenlly abnormal
Normal
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prior lo and l after Ihe estimated date of seroconversion lo
HIV.
Finally. Ihe endpoinl of cirrhosis was based on perfor-
mance of a biopsy. The transaminase levels in those biopsied
and those not biopsied suggesls lhat a highly selected
Population may have been chosen for biopsy (Table I).
Thus, the estimale of progression to cirrhosis is likely to be
an overeslimale of thal in HCV-infected haemophilic palients if
ALT levels are related to subsequenl developmenl of cirrhosis.
These results are of importance for healthcare planning
purposes and for advising haemophilic palienls about their
disease. Allhough there is no doubl thal chronic HCV
infection is a progressive disorder. it is likely thal Makris et al
(1996) have overestimated Ihe rapidily of progression for the
individual infecled with HCV alone and may have under-
estimated Ihe impacl of co-infeclion on Ihese progression
rates. Further analyses of these valuable dala will help lo
clarify Ihese issues.
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We thank Drs Lee and Sabin for their interest in our paper and
for Iheir comments. They suggest lhal we have shown 'a non-
significanl increased risk of progression in Ihose co-infecled
wilh HIV. Allhough we do nol ihink it crucial whether the
result was or was nol signilicant, it aclually was. The
remainder of Iheir commenls centre around three areas.
The time oj infection with hepatitis C. This is a difficull
Problem and we can only hazard a guess äs to the exact lime
of infection. Neither the System we used nor thal used by Lee
and Sabin (Telfer et al. 1994) is likely to be very accurate.
Allhough ii is Irue lhal almosl all concentrates used between
1978 and 1984 Iransmitled hepalilis C wilh every balch. Ihis
cannol be exlrapolaled lo other periods. Early concentrates.
especially those produced in the U.K., were made from only a
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Table I
Makris i'tal, 1996 Teller ein/, 1994 Eyster et al, 1993
Total HCV+ve patients
HIV co-infected
liver failure patients
HIV-negative
liver failure patients
138
4/36 (11-1%)
5/102 (4-9%)
255
10/103 (9-7%)
1/152 (0-6%)
156
11/97(11-3%)
0/59 (0%)
small number of donors, so HCV infection was not invariable
(Makris et al, 1993). Furthermore, many severe haemophiliacs
are likely to have received hundreds of units of plasma or
cryoprecipitate prior to exposure to concentrate and may have
already been infected with HCV before the assumed infection
date.
Lee and Sabin feel that our assumptions may not apply to
mildly affected patients and suggest we recalculate our
cirrhosis and liver failure rates restricting the analysis to
those with known infection dates. We have re-analysed our
data by calculating survival curves only for those whose date
of HCV infection was known to us, but this did not change
the results.
The HIV co-infection risk. We agree that entering HIV-
seropositivity äs a time-dependent covariate in the analysis is a
worthwhile analytical procedure. When we reanalysed our
data by this method, the results did not change. The hazards
ratio (relative risk) for cirrhosis in HIV-positive HCV carriers, äs
compared to HIV-negative patients was 4-1 (CI95 Γ4-12Ί),
whereas the original flgure was 3-9. All other estimates also
remained unchanged. Two previous cohort studies reported
on the rate of liver failure in HIV co-infected patients (Eyster et
al 1993; Telfer et al, 1994). The crude data based on total
patients reported are compared with our data in Table I.
Only one of 211 HIV-negative haemophiliacs developed
liver failure in the two other cohorts, which is surprising
considering the natural history of HCV in non-haemo-
philiacs (Tremolada et al. 1991). Moreover Darby et al
(1995) have recently reported an increased liver related
mortality among U.K. HCV+ve HIV—ve haemophiliacs.
The selection of patients for biopsy. As we mentioned in our
paper (Makris etal, 1996), liver biopsies were not performed in a
random fashion, in that patients with abnormal liver enzymes
were more likely to be biopsied. Drs Lee and Sabin are, however,
wrong in suggesting that this overestimates the incidence of
cirrhosis. In contrast, the opposite is likely to be true. We found
19 cases of cirrhosis in our cohort of 138 patients. Since a liver
biopsy was performed in <50% of the cohort, this is almost
certainly an underestimate of the true number of patients with
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cirrhosis. It would be inconceivable that we fortuitously
biopsied every case of cirrhosis from the cohort.
We remain convinced that HCV-related liver disease in
HIV-negative haemophiliacs is associated with significant
morbidity and mortality, a fact supported by the data
reported by Darby et al (1995) on the entire U.K.
haemophilic population.
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INTERFERON ENHANCED MINIMAL RESIDUAL DISEASE DETECTION IN ACUTE PROMYELOCYTIC
LEUKAEMIA
In their recent paper, Seale et al (1996) reported that PCR
sensitivity for PML-RARa detection in acute promyelocytic
leukaemia (APL) may be improved by modifying reverse
transcription (RT) and PCR conditions. Moreover, an in vitro
pretreatment of APL cells with Interferon (IFN) may also
increase the expression of the chimaeric transcript. They
1997 Blackwell Science Ltd, Britis/7 Journal of Haematology 96: 872-882
